Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Divestments: 2020-2021

Historic Divestments for Myriad Genetics (MYGN) over the last 1 years, with Sep 2021 value amounting to $379.1 million.

  • Myriad Genetics' Divestments rose 1679.81% to $379.1 million in Q3 2021 from the same period last year, while for Sep 2021 it was $400.4 million, marking a year-over-year change of. This contributed to the annual value of $8.8 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2021, Myriad Genetics' Divestments is $379.1 million, which was up 1,679.81% from $21.3 million recorded in Q3 2020.
  • Over the past 5 years, Myriad Genetics' Divestments peaked at $379.1 million during Q3 2021, and registered a low of -$21.3 million during Q2 2020.
  • In the last 2 years, Myriad Genetics' Divestments had a median value of $21.3 million in 2020 and averaged $100.1 million.
  • Data for Myriad Genetics' Divestments shows a peak YoY surged of 1,679.81% (in 2021) over the last 5 years.
  • Over the past 2 years, Myriad Genetics' Divestments (Quarterly) stood at $21.3 million in 2020, then surged by 1,679.81% to $379.1 million in 2021.
  • Its last three reported values are $379.1 million in Q3 2021, $21.3 million for Q3 2020, and -$21.3 million during Q2 2020.